Our Response to the Coronavirus Disease 2019 (COVID-19)
▼ 1. Stable supply of products and services
▼ 2. Creating and providing new diagnostic technology (Updated on June 7, 2021)
▼ 3. Prevention of further spread of infection and ensuring employees’ safety
▼ 4. Others
▼ 2. Creating and providing new diagnostic technology (Updated on June 7, 2021)
▼ 3. Prevention of further spread of infection and ensuring employees’ safety
▼ 4. Others
We at Sysmex Corporation believe that it is our mission to support the medical professionals who are on the frontline of the fight to prevent the spread of COVID-19, by ensuring continuity of the clinical testing that they perform daily in various healthcare settings around the world, so that we can overcome this difficult situation together. To this end, we are trying our utmost to ensure the stable supply of products and services. In addition, to successfully combat the COVID-19 pandemic and bring things back under control as soon as possible, we are working to develop new diagnostic technologies and prevent further spread of infection and ensure our employees’ safety.
1. Stable supply of products and services
We make it a rule to maintain sufficient stocks of products and the raw materials needed to produce them and work in close collaboration with distribution businesses, thus ensuring the stable supply of products.
To ensure that medical professionals can offer medical services without unnecessary concern, we continue our service operations, such as urgent repair of our products, by using extreme caution to prevent infection.
To ensure that medical professionals can offer medical services without unnecessary concern, we continue our service operations, such as urgent repair of our products, by using extreme caution to prevent infection.
- Updates & information on COVID-19 (Sysmex Europe GmbH)
- Updates & information on COVID-19 (Sysmex America, Inc.)
2. Creating and providing new diagnostic technology
We endeavor to halt the further spread of COVID-19 by providing medical professionals with new diagnostic technologies utilizing our global networks, as well as our proprietary measurement technologies and assay services.
Joint Research
Products and Services
Joint Research
- SARS-CoV-2 antibody status in patients with cancer during the COVID-19 pandemic in Japan (June 2, 2021)
- Kobe University and Sysmex Conducted Clinical Evaluation of the ELISPOT Method: A New Test for COVID-19 using blood - Report on T cell Immunity to SARS-CoV-2 in the Japanese Population - (December 24, 2020)
- The National Cancer Center, the National Center for Global Health and Medicine, and Sysmex Corporation Evaluate a SARS-CoV-2 Antibody Test with Support from the Japan Health Research Promotion Bureau - Performance Report on an Antibody Detection Reagent Using Clinical Specimens - (July 3, 2020)
- The City of Kobe, Kobe City Medical Center General Hospital, and Sysmex Corporation Working to Launch from Kobe the Clinical Implementation of a New Test for the Novel Coronavirus - Collaborating with Medical Institutions of the Foundation for Biomedical Research and Innovation at Kobe to Strengthen Measures Allowing Early-Stage Diagnosis and Prediction of Severity - (July 3, 2020)
Products and Services
- Th2 Chemokine TARC Kit "HISCL™ TARC Assay Kit" is Approved for an Additional Indication as an Auxiliary for Assessment of COVID-19 Aggravation risk (June 7, 2021)
- Sysmex Relocates its PCR Testing Laboratory to its Research and Development Center for Expanded Functions (May 18, 2021)
- Sysmex Obtains Manufacturing and Marketing Approval for Novel Coronavirus Detection Reagent (RT-PCR Method) - Building a Self-Sufficient Production System in Japan for a Stable Supply of PCR Testing Kits - (April 15, 2021)
- Insurance Coverage Received for HISCL™ IFN-λ3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in SARS-CoV-2-Positive Patients (February 12, 2021)
- Sysmex Obtains Marketing Approval for the HISCL™ IFN-3 Assay Kit, a Test Kit to Assist in Determining Exacerbation Risk in Novel Coronavirus (SARS-CoV-2)-Positive Patients (December 23, 2020)
- Sysmex Obtains Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent - Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (November 11, 2020)
- Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent - Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (September 29, 2020)
- Sysmex to Launch Novel Coronavirus (SARS-CoV-2) Antibody Lab Assay Service and Antibody Measurement Reagents (for Research) - Using the HISCL™-5000/HISCL™-800 Fully Automated Immunoassay Systems to Realize SARS-CoV-2 Antibody Detection - (July 3, 2020)
- The Use of Saliva in PCR Tests for the Novel Coronavirus - Expanding the Scope of Sample Types - (June 9, 2020)
- The City of Kobe, Sysmex, and SRL Configure and Begin Operating a PCR Testing System for COVID-19 within the Kobe Biomedical Innovation Cluster (May 18, 2020)
- Sysmex New Zealand And ESR Collaborate On National COVID-19 Results CDR (May 11, 2020)
- Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method) - Aiming for early introduction of test kits for in vitro diagnostic medical devices in medical institutions - (March 27, 2020)
3. Prevention of further spread of infection and ensuring employees’ safety
Sysmex Corporation and its affiliated companies across the globe are acting to prevent the spread of COVID-19 by way of our business activities, and we are taking every measure to ensure the safety of our employees, their families, and others concerned.